Bristol-Myers To Pay Nektar $1.85B In Cash, Stock As Part Of Collaboration Pact
February 14, 2018 at 09:35 AM EST
Bristol-Myers Squibb and Nektar Therapeutics announced the companies have executed a global strategic development and commercialization collaboration for Nektar's lead immuno-oncology program, NKTR-214.